Bumetanide nasal spray is bioequivalent to oral bumetanide in 68 healthy adults; Esperion is targeting heart failure care before a 2027 CMS payment model.
|Articles|May 17, 2012
Healthcare Reform: GOP Preps Plan for Ruling on Law
Advertisement
House Republican leaders are quietly hatching a plan of attack as they await a historic Supreme Court ruling on President Barack Obama’s health care law.
If the law is upheld, Republicans will take to the floor to tear out its most controversial pieces, such as the individual mandate and requirements that employers provide insurance or face fines.
Read the full story:
Source: Politico
Advertisement
Related to this article
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Remibrutinib (Rhapsido; Novartis) is the only treatment with approved uses in both chronic spontaneous urticaria and symptomatic dermographism.
Leukemia survivors given high-risk ALL therapy had hip bone density about 90% of matched controls, without the partial normalization seen in other groups.
A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Sacral neuromodulation is still considered the gold standard for refractory overactive bladder, with tibial nerve stimulation a less invasive option.
FDA approved tucatinib maintenance for HER2-positive metastatic breast cancer following induction therapy based on the 654-patient HER2CLIMB-05 trial.
A meta-analysis found teleophthalmology satisfaction comparable to in-person eye care, but showed a gap between recommending it and reusing it.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
Predoc and Nebraska Cancer Specialists: Not Letting the Fax Be the Fumble
3
Sacral Neuromodulation Still Seen as OAB Gold Standard in Review
4
FDA Approves First Symptomatic Dermographism Treatment
5